Julia Schopick on the LDN Radio Show 11th September 2019

Linda Elsegood: Today, my guest is Author Julia Schopick who wrote the book Honest Medicine and she has a new book out now called The Power of Honest Medicine. Thank you for joining us today, Julia. 

Julia Schopick: I'm delighted to be with you, Linda, thank you. Thank you for inviting me.

Linda Elsegood: Tell us a bit about the first book first, please.

Julia Schopick: Okay. I'd be delighted to. My first book, Honest Medicine, which was published in 2011 resulted from experiences I had with my husband, who was a 15-year survivor of a cancerous brain tumour. And what I found was that, then, you know, things that we did for him, including nutrition, you know, things like that made him live longer. He was supposed to live three years maximum, he lived fifteen, and I found that the doctors were not at all interested in anything we were doing, they did take credit for him being a miracle patient, by the way. They didn't deny, you know, but so I decided that there must be treatments that doctors don't know about, but that is very, very effective and that patients would want to know about.

So, I wrote Honest Medicine. I really looked for, you know, these treatments they have to beat, I won't go into detail, but they had to be really reputable science-based treatments. One of them was a silverlon, the treatment that healed my husband's non-healing wound, head wound, when he wasn't healing from the second craniotomy, the second brain tumour surgery and then, of course, there was intravenous alpha-lipoic acid, you know, for liver disease and some cancers, and the ketogenic diet for pediatric epilepsy and finally, Low Dose Naltrexone. What I found was, you know, I went on over 200 radio programs and the book was reviewed in lots of places.

Everyone was more interested in LDN, Low Dose Naltrexone. So I decided that another book should be just about LDN. So that's a brief snapshot.  

Linda Elsegood: So the second book, tell us a bit more about that. 

Julia Schopick: Well, the second book, you know, was very long and calming. It took me several years to complete it. I wanted it to be, it was, you know, about Low Dose Naltrexone, but I wanted it to be universal. I wanted it to be international. So I got very active on Facebook, and I use Facebook to, you know, get the people who were going to be part of it. You, as you know, are part of the book and people from all different countries were part of the book. And I wanted it to be representative of not only the first book, Honest Medicine, the stories about LDN were all about people with MS, and this one has MS, but several other autoimmune diseases as well. It's just a very, I think, a very interesting book, you know, especially for the lay public because to get the word out about LDN for all different conditions

Linda Elsegood: And from all the radio shows you have done and all the publicity you have done. What would you say has been the main condition that LDN is being used for? that you've been dealing with? 

Julia Schopick: Oh, what an interesting question. I haven't, you know, I haven't really analyzed that, but I would say probably, you know, MS is its poster child, you know, that, I mean, that was the first of the MS patients, you know, we're the first ones to get active in getting the word out about LDN.

But I also think fibromyalgia is a big one and a Crohn's disease. Oh, my God. Crohn's disease, even Parkinson's, you know, the conditions that I write about lupus, I think all of them I'm hearing from people with all of them. And I try to pick the ones, by the way, Linda, that was most, do you want to say popular?

I don't know if that's the right word, but you know, that most people had, Hashimoto's was a big one I thought of including Graves' disease. But Hashimoto's is actually, you know, there's a, there's a website, excuse me, a Facebook group dedicated to the thyroid, but most of the people who participate are Hashimoto's.

So I would say that. If I sound like I'm hedging in a sense I am because I think that all of these conditions are equally important. What do you find you, you interview lots of people, even many, many more than I do. What do you find? 

Linda Elsegood: There are hot topics at the moment, as you probably know.

And the biggest one, I mean, we're doing a documentary to address the opioid crisis. And I know maybe ten pain specialists who are using ultra-low-dose naltrexone to wean people off of opioids. It's really, really interesting. I don't know how much you know about that. 

Julia Schopick: Not enough. Okay. Um, yes, very interesting.

Linda Elsegood: So what they do is use micro-dosing. So I mean, if you think. You know, 0.5 milligrams of LDN is low. The ultra-low dose is 0.001; it's so minuscule. But when used with an opioid, it makes the opioid far more effective. So that means you can actually titrate the opioid down whilst titrating the ultra-low-dose naltrexone up and these pain specialists are getting patients who are legal drug addicts, should we say, because they have become addicted to prescription-only drugs through no fault of their own but can't come off them because they're so addicted. These pain specialists are managing to get patients off without withdrawal and onto LDN, and it's more effective than their pain medications were, but without the awful withdrawal. It's just an absolutely amazing story. So that to me is what I've been working on the last quite a few months now, and I find that totally amazing. And what the doctors say, Oh, well, it took quite a while. It took five weeks or something. I'm thinking, what, you know, that is such a short period of time and I've had the pleasure when I went to America to talk to some of these patients who have managed to come off the opioids. And it's just—mind-blowing. Absolutely mind-blowing. But of course, the pain that people have. I mean, you mentioned fibromyalgia there, but there are so many other types of pain that LDN is being used for.

And I interviewed a doctor, he was a podiatrist, and he was really interesting. Now it's being used by dentists. It's been used in eyedrops, not only for Sjogren's but other ocular eye problems. And it just keeps growing. You know, the list of conditions that LDN can help with is growing and growing.

Julia Schopick: So much so exactly. In the United States. 

Linda Elsegood: Yeah. And we are going to have a second LDN book, which will address more conditions because obviously there's only so much you can get in a book cause you know. But dementia is another really good one, Alzheimer's, memory loss as to quite a big, hot topic.

But I could talk all day and every day, and l probably do about LDN, but it's so interesting. It's evolving the whole time and with the microdosing and we're finding, okay. In your opinion, what would you say the success rate is? Mainly for people with chronic conditions using LDN. 

Julia Schopick: Pretty high. 

Linda Elsegood: Give me a number at a rough number.

Julia Schopick: Um, would you say 80% 

Linda Elsegood: okay, let's go for 80%, so that's 20% LDN isn't working for, but we have to use the ultra-low dose. And doing different dosing protocols depending on the condition, whether it's a mental health condition where they're using double dosing, sometimes they're using three times a day dosing for different conditions, but by tailoring the dose in microdoses going up, coming down, working with an experienced prescriber, that 20% of people who haven't had success with LDN, it's nearer to the hundred than the 80%. 

Julia Schopick: So this is like the huge, this is like a huge story.

And now my question, I have a question for you if you don't mind.  How can we get the mainstream media to, this is one of my big bugaboos, you know when I go on interview shows, but also in the book and The Power of Honest Medicine that the mainstream media, you know, because they're so controlled, at least in this country, by pharma? They wouldn’t do that but maybe for the opioid crisis they would. 

Linda Elsegood: well, the documentary will be out soon we’re finishing filming it next week. But what we did, we did a pilot trial a few weeks ago in America. I was invited to the PCCA, which is the compounding pharmacy, whatever the PCCA stands for ...

Julia Schopick: Yeah exactly 

Linda Elsegood: And they wanted me to tell my story and that of the LDN Research Trust and what we'd been doing and it was quite funny. I did a talk in Madison, in Wisconsin as well, and another one we did in New Jersey. So there were three very, very exhausting and tiring all the different meetings that went along with the talks.

And we did some filming of the pain documentary but we're not going to have a conference next year. The conference will be in 2021. But next year it’s planned that every four months we will have a whistle-stop tour in a state or  States and do seminars for mainly prescribers.

But patients can come as well. And this, this was the two talks that I did, not the BCCA one, but the other two and the one in New Jersey had around 200 - 250 doctors there. It was amazing. So actually taking the word out there and teaching the doctors, it wasn't me doing the teaching, by the way, and showing the facts and the research and new dosing protocols and getting doctors on board to listen to the new way. And some of these doctors had been prescribing LDN for ten years or so, and they were totally blown away with the new concept and idea so that we don't have this 20% that LDN isn't working for. They're the people that we're trying to help.

When I say we're tried to help, I mean we're trying to help everybody, but we wanted to have a better success rate, and it's proving to be working. So next year, by putting in the effort and doing more training, we're going to see if we can then roll it out. And doctors are really, really busy. So it's going to be pharmacists that will become educators who will be educating the prescribers in their area. So it's all to do with education and training and that is how the word is going to ... LDN is just going to explode this next 18 month it’s going to be phenomenal. 

Julia Schopick: And you said you're doing a documentary on the ultra-low dose for opioid? And when will that come out? 

Linda Elsegood: The filming will finish next week. It takes—a long time for editing. I mean, we'll probably take another six months after filming is finished to have it all edited and put together but it is going to be amazing. I mean, we have so many really good pain specialists who were so eager and keen to be filmed sharing their experiences.

Julia Schopick: Would you be open to having that be shown on HBO or Netflix? 

Linda Elsegood: Well, we would, yes. 

Julia Schopick: Let's try to talk about that, Uh, not on the air. Okay. 

Linda Elsegood: Okay. Because whatever I can do, you know, I will. 

Julia Schopick: and that, that, by the way, that would do it. Do you know what I'm saying? Because then you would get the people who are addicted and want to get off.

I mean, who doesn't? They're not, you know, the doctors aren't prescribing the opioids in many cases. So the patients, if they were on HBO or Netflix, the patients would start demanding it. And then, you know, what happened in Norway with Frank Mel, with his documentary in Norway. the prescribers went from 300 to 15,000 overnight. I mean, the prescriptions. Yeah. And so my theory is that, if we can get something about LDN on something like HBO or Netflix, you know, a station by the way that does not depend on advertisers, because who do you think is most, is most of the advertisers in most of the media is, of course, pharma. So, uh, but you would be open to it? 

Linda Elsegood: Oh, yes. Everywhere and anywhere we could get it out there for sure. 

Julia Schopick: I will put my thinking cap on, and if you don't mind, I will start taking it up a little bit. 

Linda Elsegood: Okay. 

Julia Schopick: Yeah. All right. It's exciting. 

Linda Elsegood: It's very exciting. And this is why I am just so busy the whole time.

And it's too exciting to stop, you know, got to keep going. 

Julia Schopick: You know, from a, I call you one of my LDN heroes in The Power of Honest Medicine and I was very careful because all of the people in my book are heroes and heroines. Do you know what I'm saying? I didn't want to but I did single out four people, and you were one of them. And you know why I mean you, you're the Energizer bunny, you know, and you won't quit until you, you make an, you're gonna. You are succeeding. I don't mean you're going to succeed. You are succeeding. It's amazing. 

Linda Elsegood: Yes. Well, I'm stubborn. I think that's what it is.

I've started, so I want to finish, but I've been doing this 15 years now and. We had last Monday we had two people die that we know very, very well. In a 24 hour, less than a 24 hour period, and that knocked me for six and I was thinking, okay, so this is what I've done in 15 years. Have I got 15 years left?

How many more years have I got? Can I complete everything that I would like to complete in my lifetime? It's a bit of a reality check, isn't it? You know, I'm not, I'm not a young person anymore but still, I hope I have many years left to continue.  

Julia Schopick: you know, your legacy is huge, and I know you do have many.

You know what? You're too stubborn to die. Isn't that great? 

Linda Elsegood: I do believe though when you're time is up your time is up. 

Julia Schopick: Well I think you have a lot more to do and I'm very excited about this ultra-low dose. Uh, you know, for the opioid, and I think this could be the way we get to mainstream media, as I said, not with stations that are pharma, you know, supported.

But now with cable, there's so much more. And with things like Hulu and Netflix and, you know, there are so many more options. So this may, this may be it. 

Linda Elsegood: Well, we can hope. But then in your book, Julia. Off the top of your head, and I'm sure you must have a list there. What conditions do you cover?

Julia Schopick: Okay. The conditions that I cover in the book, and you're right, I do have a list, they are, let me get them out for you: They are MS, Chronic Fatigue Syndrome, Lupus, Fibromyalgia, Hashimoto's, Crohn's, Parkinson's, Psoriasis. Oh, I didn't mention that the first time around. Um, and also, are you ready for this?  I decided to include one that is not an autoimmune or even autoimmune connected, and that's Haley Haley Disease and it's a rare skin condition. I'll bet you know why I decided to include it, but I'm gonna tell the listeners anyway, I was gobsmacked, as we say, in England, when I heard that LDN, you know how LDN is hardly ever covered by the mainstream press, although that is getting better JAMA -  Journal of the American Medical Association, the JAMA dermatology, a magazine journal, actually did case studies, published case studies of Haley Haley Disease being helped by LDN.

And I was like, Oh my God, this is big. Do you know?  So that is one that I included, even though it was not an autoimmune disease. It's a genetic disease.  I was talking with Jackie Bihari about it, and I don't know the name of it, but there is a related autoimmune disease, but it is not Haley Haley.  So it works not only as, you know, it works for not only autoimmune but many others, so those are the conditions. 

Linda Elsegood: I was surprised because of the people with rheumatoid arthritis, you can understand that that's an autoimmune disease but people with osteoarthritis, it also works for, after speaking to pain specialists, there doesn't have to be an autoimmune component.

LDN helps with pain. Yeah. You know, and all of this is just coming out daily. You know, there's more coming out all the time. 

Linda Elsegood: Yes. Yes, exactly. So it's really exciting. And, you know, we are also going to put together an ebook for our 15th anniversary, which is this year. I haven't had a chance to

promote that too much right now, but I will be later on where we will be having stories of patients from all around the world, but not just patients from prescribers and pharmacists and researchers, which will be really interesting. It will be like an ebook, we're not having it printed. We have it just as a  free download. So that would be interesting. Just as a celebration of the 15 years.  

Julia Schopick: I don't know how you do it all, but I'm going to ask a favour. Is there any way that I could get a sneak preview of the LDN, the ultra-low, you know, with the opioid, when it's done before you would do it because I would love to see what I could do to get it out there in the mainstream.

Linda Elsegood: Yep. Remind me nearer the time points it's done. 

Julia Schopick: Yeah. You know, because it's, it's much more powerful if you say, you know, it's powerful. If I say, I know this woman, I know her work, and by the way, here are links to her other work. Do you know what I'm saying?  but if you say, I have seen it, and it's most impressive that can really help. So I'm excited. 

Linda Elsegood: I'm excited. How it's all evolved and as I say, these protocols to help those people where LDN, for whatever reason, they couldn't get the results to actually be able to increase that number. 

Julia Schopick: What do you think is the reason why some people just don't have any luck with it? You know, the 20% we were talking about?

Linda Elsegood: Because they might be sensitive, they might need to do it very gradually, very slowly.  They might need to take it twice a day, three times a day. Yeah. Sometimes you have to go higher, but you need a prescriber who understands how to do the titration. But you know, for the most majority of people, LDN works really well without having to go to those measures. But there are some people who need that help and support.

Julia Schopick: I think there's another reason and that is sometimes you know, on Dr Gluck's website http://lowdosenaltrexone.org/ he has an article about why choosing the right compounding pharmacy is important. And some of them say they do it, but they really don't.

Linda Elsegood: But even the ones that do it correctly with the rapid release. The patients still don't get 100% or more than 90% or 80%. So it's not just the compounding. There are further reasons, you know, and a lot of these compounding pharmacies listen to the patients if they want a different filler or different formula. They're open to that, it’s what compounding pharmacies do, yeah. So, you know, not meaning to contradict you and please don't think that that's why I was trying to do, 

Julia Schopick: I'm out to learn. 

Linda Elsegood: But I would still think there are other reasons, you know, just by everybody doing the same formulation with the same product, they're not going to be able to help everybody how it is at the moment. It is really, you need to tailor that dosing protocol for the patient, which is really exciting, very exciting, and the prescribers are excited by it too.

Julia Schopick: And they're growing. I think I asked Crystal. Now I know that there are many lists out there of prescribing doctors, but I believe she told me that it's over a thousand now on her list.

Linda Elsegood: So it's pretty good, huh? 

Julia Schopick: And her list doesn't have everybody, I'm sure. 

Linda Elsegood: Well, we had eight and a half thousand, so I'm surprised her list is so low. But with, we have in the UK new GDPR laws, which are data protection, and we now can only list on the website prescribers or pharmacists that have given us their permission to be listed in 2019 if they haven't given us our permission, they had to be removed.

And we were telling people. And I think we did a big culling, I think at the end of March, we have sent ten emails to faxes, and we now have a lady who's literally calling all these prescribers and saying, you've now been removed, would you like to be back on the list? Fill in this form? So any pharmacist or prescribers out there who are now not on our website, please get in touch. We would love to put you back. But it is an annual requirement that we have to check. And I understand we have to now have a data protection officer who does a fantastic job if you were listening. Thank you, Laurie. But we have to check because you know, people die. People stop practising. People move away. So the information you have. Not necessarily if they've been on the list for 15 years, like some of them had are still there that the listings aren't current. So by doing it annually, you know, at least at the end of the year, that information is only a year old and then you have to start the next year again. It's an awful lot of work. You would not believe the months that it's taken, but still, we weathered the storms and with Brexit, who knows what else we have to do. But we've come to the end of the show. Julia, 20 minutes went to 30. And I thank you very much for being our guest today. 

Julia Schopick: Oh, well, I want to thank you for inviting me and this is wonderful. Thank you so much. 

Linda Elsegood: Thank you, Julia. 

This show is sponsored by Mark drugs who specialize in the custom compounding of medications, assuring that the client gets the proper prescriptions for their unique needs and conditions. They work with practitioners integrating knowledge and treatment of experts to create comprehensive health plans.

Visit https://www.markdrugs.com/ or call Roselle 630.529.3400 or Deerfield (847) 419-9898.

 

Any questions or comments you may have please email me: Linda@ldnrt.org I look forward to hearing from you. Thank you for joining us today. We really appreciated your company. Until next time, stay safe and keep well.